Personalized Treatment of Patients With Multiple Sclerosis: A Case Report and Literature Review

Read full text Summarise with VIRAT
Authors: Fengjun Wang, Han Wang, Yu Zhang, Guoxun Zhang
Cited by: 0
References: 8

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Managing multiple sclerosis (MS) with a highly active disease course presents significant challenges, particularly regarding the timing of therapeutic escalation and the preservation of brain volume. We present a personalized management strategy for a 36‐year‐old male with relapsing‐remitting MS (RRMS) who experienced initial misdiagnosis, frequent relapses, and a transition to a highly active phenotype triggered by COVID‐19 infection. By comprehensively evaluating prognostic factors, including spinal cord involvement and incomplete recovery from relapses, we transitioned the patient from moderate‐efficacy therapies (Siponimod, dimethyl fumarate) to high‐efficacy therapy (HET) with Ofatumumab. This timely escalation resulted in the stabilization of the Expanded Disability Status Scale (EDSS), cessation of new inflammatory activity, and a Brain Volume (BV), suggesting the resolution of pseudo‐atrophy or neuroplasticity. This case underscores that early identification of high disease activity and rapid escalation to HET are critical for stabilizing long‐term disability and potentially preserving brain integrity in the Chinese clinical context.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Polyomavirus and related diseases Psoriasis: Treatment and Pathogenesis

Publication details

Journal / source
Medicine Bulletin
Volume
2
Issue
3
Pages
312–318
Publication date
30 March 2026
Language
EN